Comment from CHRISTINE TAYLOR
CHRISTINE TAYLOROpposeIndividual
Summary: A representative from a clinic (appearing as an individual) argues against the FDA's decision to move specific peptides to Category 2 of the Bulk Drug Evaluation list. They contend that these compounds are highly beneficial to patients with minimal safety risks and request that the FDA reconsider the move to prevent harm to their patients.
To whom it may concern,
The FDA's decision to move the peptides listed below to Category 2 of the Bulk Drug Evaluation list has posed tremendous harm to the patients of our clinic that depend on the benefits of these medications. According to the FDA, pending further evaluation, drug products compounded using these peptides are not eligible for pharmacy compounding. Our belief remains firm that these compounds are highly beneficial to patients, supported by available data that illustrates minimal safety risk as well as the extensive health benefits. Please reconsider this move as it will be detrimental to the health of many patients.
AOD-9604
BPC-157
CJC-1295
Dihexa
DSIP
Epitalon
GHK-Cu (Injectable ONLY)
Ipamorelin
Kisspeptin
KPV
LL-37
Melanotan II
MK-677 (Ibutamoren Mesylate)
Selank
Semax